Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Amir R. Aref, David Barbie, editors.
    Contents:
    1. Introduction to Ex Vivo Cancer Models
    2. Patient-derived Xenografts in Oncology
    3.Organoid Culture: Applications in Development and Cancer
    4. Microfluidics and future of cancer diagnostics
    5. Advancing techniques and insights in circulating tumor cell (CTC) research
    6. The Cancer Secretome
    7. An overview of the tumor microenvironments and future of cancer therapy.
    Digital Access Springer 2017
  • Book
    Jaime Ardiles Franco, Víctor Palomino Chinchay.
    Print [between 1986 and 1988]
  • Article
    Phillips CI, Gore SM, Macdonald MJ, Cullen PM.
    Br J Ophthalmol. 1977 May;61(5):349-53.
    Guttae atenolol 4% (Tenormin), a pure beta1-blocking (i.e., cardioselective) drug, produced a median overall fall of 5-6 mmHg (range 3-2 to 13-2 mmHg) in the first tonometrised eyes of 7 patients with open-angle glaucoma or ocular hypertension and 1 with closed-angle glaucoma (off any treatment for the whole of the day preceding each test day) after allowance for an 'effect' of guttae saline 0-9%, in a double-masked, cross-over trial. By a Wilcoxon matched pairs rank test this was significant at the P less than 0-05 level. The median overall fall of 3-5 mmHg (range 0-8 to 10-8 mmHg) in the second-tonometrised eyes of 7 patients (1 of the 8 contributed only 1 eye) was also significant (P less than 0-05). In 2 patients who had been treated with guttae atenolol 4% daily 3 X for 1 and 2 months there is evidence that, on replacing the atenolol 4% with saline 0-9%, a rise of pressure of around 3 mmHg occurred 2 and 3 and 5 days later, i.e., the drug still retained its effectivity (slightly reduced) after 1 and 2 months.
    Digital Access Access Options